A day after surpassing its own expectations with dazzling Phase III data for its lead pipeline candidate, the oral ulcerative colitis (UC) drug obefazimod, Abivax (Euronext Paris and NASDAQ: ABVX) so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback